It is plausible that these HLA alleles differ in their capacity to present tumor-derived peptides to T cells, and possibly to interact with receptors such as KIRs, LILRBs and CD94/NKG2 on NK and T cells, thereby differentially regulating antitumor responses. The gene discussed is KLRC1; the disease is neoplasm.